PRKN
If any of the terms on this page are unclear or you want to learn more about them click here!
PRKN, which encodes Parkin, is one of the most important causes of familial early-onset Parkinson’s disease and is among the best-established monogenic Parkinson’s Disease (PD) genes. Parkin-related disease often starts young and can be clinically similar to PINK1-related disease.
Normal function
Parkin is an E3 ubiquitin ligase, meaning it helps tag damaged or unneeded proteins with ubiquitin so they can be processed by cellular degradation systems. In the mitochondrial quality-control pathway, Parkin is activated downstream of PINK1 and helps label damaged mitochondria for removal.
Mutation and effect
Most disease-causing PRKN mutations lead to loss of Parkin function. While upstream proteins can still signal that mitochondria are damaged, that signal is not able to be transmitted to the autophagosome to carry out mitophagy. This reduces the cell’s ability to clear damaged proteins and defective mitochondria. As a result, stressed cellular components can accumulate rather than being efficiently removed.
Key mechanisms involved
The key mechanisms are defective ubiquitin-mediated quality control, impaired mitophagy, and downstream mitochondrial stress. Parkin sits at an important junction between proteostasis and mitochondrial maintenance, which is one reason this gene has had such a large influence on the field’s understanding of Parkinson’s biology.
Implications for treatment
As of right now, treatment still mainly targets symptoms, especially with levodopa, which many patients respond to well. The larger implication is mechanistic: PRKN helped establish that boosting cellular cleanup systems and mitochondrial quality control might be a rational strategy in PD, especially in genetically defined subgroups.
Research focus
Research is focused on clarifying how Parkin variants alter cellular function, how PRKN loss interacts with other PD pathways, and whether the PINK1-Parkin axis can be therapeutically restored. Parkin remains one of the most important entry points for studying the connection between mitochondrial dysfunction and neurodegeneration.
Inheritance
PRKN is the single most common cause of the early-onset, inherited form of Parkinson's, showing up in somewhere between about 3% and 15% of early-onset cases, depending on the population. People with two changed copies typically start showing symptoms around age 31. It's also recessive, so if both parents happen to be carriers without knowing it, each of their children has a 25% chance of inheriting the disease.
Sources
- Narendra, D. P., Jin, S. M., Tanaka, A., et al. (2024). The role of PINK1-Parkin in mitochondrial quality control.
- Brüggemann, N., & Klein, C. (2020). Parkin Type of Early-Onset Parkinson Disease.
- Clausen, L., Okarmus, J., Voutsinos, V., et al. (2024). PRKN-linked familial Parkinson’s disease: cellular and molecular mechanisms of disease-linked variants.
- Fiesel, F. C., Caulfield, T. R., Moussaud-Lamodière, E. L., et al. (2015). Structural and functional impact of Parkinson disease-associated mutations in the E3 ubiquitin ligase parkin.